203 related articles for article (PubMed ID: 37499988)
1. PI3K signaling-regulated metabolic reprogramming: From mechanism to application.
Su WY; Tian LY; Guo LP; Huang LQ; Gao WY
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188952. PubMed ID: 37499988
[TBL] [Abstract][Full Text] [Related]
2. Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells - A potential contribution to the predictive, preventive, and personalized medicine.
Mazurakova A; Koklesova L; Csizmár SH; Samec M; Brockmueller A; Šudomová M; Biringer K; Kudela E; Pec M; Samuel SM; Kassayova M; Hassan STS; Smejkal K; Shakibaei M; Büsselberg D; Saso L; Kubatka P; Golubnitschaja O
J Adv Res; 2024 Jan; 55():103-118. PubMed ID: 36871616
[TBL] [Abstract][Full Text] [Related]
3. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
Front Immunol; 2021; 12():774103. PubMed ID: 35250965
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic regulation of tumor metabolic reprogramming.
Tarrado-Castellarnau M; de Atauri P; Cascante M
Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.
Lien EC; Lyssiotis CA; Cantley LC
Recent Results Cancer Res; 2016; 207():39-72. PubMed ID: 27557534
[TBL] [Abstract][Full Text] [Related]
6. NOX4-Derived ROS Mediates TGF-
Su X; Yang Y; Guo C; Zhang R; Sun S; Wang Y; Qiao Q; Fu Y; Pang Q
Oxid Med Cell Longev; 2021; 2021():5549047. PubMed ID: 34257808
[TBL] [Abstract][Full Text] [Related]
7. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.
Tian LY; Smit DJ; Jücker M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768977
[TBL] [Abstract][Full Text] [Related]
8. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
[TBL] [Abstract][Full Text] [Related]
9. PI3K signaling in cancer: beyond AKT.
Lien EC; Dibble CC; Toker A
Curr Opin Cell Biol; 2017 Apr; 45():62-71. PubMed ID: 28343126
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol Phosphate 5-Kinase Iγ and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth.
Thapa N; Choi S; Tan X; Wise T; Anderson RA
J Biol Chem; 2015 Jul; 290(30):18843-54. PubMed ID: 26070568
[TBL] [Abstract][Full Text] [Related]
11. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism.
Hoxhaj G; Manning BD
Nat Rev Cancer; 2020 Feb; 20(2):74-88. PubMed ID: 31686003
[TBL] [Abstract][Full Text] [Related]
12. CD38 is involved in cell energy metabolism via activating the PI3K/AKT/mTOR signaling pathway in cervical cancer cells.
Liao S; Liang L; Yue C; He J; He Z; Jin X; Luo G; Zhou Y
Int J Oncol; 2020 Jul; 57(1):338-354. PubMed ID: 32319590
[TBL] [Abstract][Full Text] [Related]
13. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
Front Immunol; 2022; 13():831636. PubMed ID: 35392088
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes.
Malayil R; Chhichholiya Y; Vasudeva K; Singh HV; Singh T; Singh S; Munshi A
Med Oncol; 2023 May; 40(6):174. PubMed ID: 37170010
[TBL] [Abstract][Full Text] [Related]
15. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
16. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
17. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
[TBL] [Abstract][Full Text] [Related]
18. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT signaling pathway and cancer: an updated review.
Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
